Business Model Breakdown
How ProQR Therapeutics NV Makes Money
PRQR
Market Cap
$207M
Annual Revenue
$6M
Profit Margin
-258.1%
The Short Version
ProQR Therapeutics is a biotechnology company focused on developing therapies for genetic diseases using its proprietary Axiomer® RNA editing platform. Essentially, it's a research and development firm that aims to 'correct' genetic errors in RNA to treat diseases. The company does not currently generate revenue but invests heavily in R&D to advance its pipeline of drug candidates. If successful, its business model would transition to licensing its technology to larger pharmaceutical companies, receiving milestone payments and royalties, or bringing its own drugs to market and generating revenue through sales, primarily targeting rare diseases with high unmet needs.
Where the Revenue Comes From
No current revenue streams; future revenue expected from licensing agreements or product sales
Who buys: Future customers would be patients with genetic disorders; potential partners would be larger pharmaceutical companies interested in the Axiomer platform.
Why It Works (Competitive Advantages)
- ✔Proprietary Axiomer® RNA editing platform technology and related IP
- ✔Strategic partnership with Ginkgo Bioworks for AI-driven drug discovery
Economic Moat: None (Intangible Assets/IP)
What Our Analysis Says
DVR Score as of April 21, 2026
ProQR remains an ultra-high-risk, highly speculative investment focusing on its unproven Axiomer® RNA editing platform. The previous score of 7 reflected the catastrophic failure of its prior lead asset and a complete strategic pivot. The current score of 9 reflects a slight positive shift due to recent tangible progress. The company has expanded its RNA editing pipeline, initiated a strategic AI partnership with Ginkgo Bioworks, and extended its cash runway into mid-2027. A key near-term catalyst is target engagement data in H1 2026 for the Axiomer platform. While these are positive developments demonstrating execution on the new vision, the platform is still unproven in humans, no revenue is generated, and significant scientific, clinical, and financial risks (future dilution) persist. 10x growth potential within 3-5 years is a long shot, dependent on multiple successful clinical advancements and substantial capital raises.